Navigation Links
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
Date:2/29/2008

riteria including the MADRS. Doses of 50 mg, 150 mg and 300 mg of SEROQUEL XR were studied in the MDD program.(4)

In 2007, SEROQUEL XR was approved in the U.S. for the treatment of schizophrenia in adult patients and for maintenance treatment of schizophrenia in adult patients. Last month, AstraZeneca announced the submission of two separate sNDAs to the FDA for SEROQUEL XR to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder. The FDA has not completed its review of these submissions. In addition to the submission for MDD, clinical development programs are ongoing and regulatory filings are planned for SEROQUEL XR in other indications.

Launched in 1997, SEROQUEL(R) (quetiapine fumarate tablets) has been prescribed to millions of patients worldwide. It is approved in 88 countries for the treatment of schizophrenia, in 79 countries for the treatment of bipolar mania, and in 11 countries including the U.S. for the treatment of bipolar depression.

Important Safety Information for SEROQUEL and SEROQUEL XR

SEROQUEL XR is indicated for the acute and maintenance treatment of schizophrenia. SEROQUEL is indicated for the treatment of depressive episodes in bipolar disorder; acute manic episodes in bipolar I disorder, as either monotherapy or adjunct therapy to lithium or divalproex; and schizophrenia. Patients should be periodically reassessed to determine the need for treatment beyond the acute response.

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death, compared to placebo (4.5% vs 2.6%, respectively). SEROQUEL and SEROQUEL XR are not approved for the treatment of patients with dementia-related psychosis. (See Boxed Warning.)

Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
2. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
3. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
4. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
5. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
6. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Cephalon Submits Supplemental New Drug Application for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 Pfanstiehl ... Mannose (USP/NF, EP), manufactured in the ... "Mannose has long been recognized for playing a ... a growing body of evidence that media supplementation ... consistency of protein glycosylation," according to Dr. ...
(Date:10/1/2014)... (PRWEB) September 30, 2014 Today ... initial round of grants for the Brain Research ... that aims to develop and revolutionize new methods ... of the human brain. This first round of ... year 2014 was allocated to more than 100 ...
(Date:10/1/2014)... September 30, 2014 Award winning ... announces four new-hosted collaboration bundles that combine ... high quality conferencing experiences for low, flat rate ... choose from, businesses have optimized solutions to meet ... include audio only minutes (1K, 5K, 10K ...
(Date:10/1/2014)... October 01, 2014 The U.S. Department ... Southern Illinois University Edwardsville as part of the Trade ... The funding is co-administered by the Department of Labor ... Secretary of Labor Thomas E. Perez and Secretary of ... in job-driven training grants to nearly 270 colleges across ...
Breaking Biology Technology:Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3SoundConnect Launches New Audio, Web and Video Bundles 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4
... Clinical Study Demonstrates Breakthrough Dose-Sparing Formulation,That Increases Stockpile ... Doses in a Pandemic Situation Sanofi pasteur, ... showing that its new investigational H5N1 pandemic influenza,vaccine ... response,at the lowest dose of H5N1 antigen reported ...
... often deal with the same problems, but they use ... can be difficult, if not impossible., A new $2.9 ... the National Science Foundation (NSF), will help bridge this ... solve common problems a range of scientists face., The ...
... 17 DaVita Inc.,(NYSE: DVA ) today announced ... Conference in London on Thursday, September 20, 2007 at ... access the live webcast, go to http://www.ibb.ubs.com, ... page, followed by the webcast link,listed next to the ...
Cached Biology Technology:Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 2Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 3Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 4Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 5CCMR gets $2.9M for training grad students in nanoscale science 2
(Date:10/2/2014)... SHELTON, Conn. , Oct. 2, 2014 NXT-ID, ... focused on the growing mobile commerce market, announces the airings ... Money and Mad Money. The national ads resumed ... will air October 2 nd and October 3 rd ... The continuing ads that began airing on CNBC ...
(Date:10/1/2014)... take a healthy salad up a level by growing ... in leafy greens. , "In the long run, one ... the salad or making a pill from the plant ... at Case Western Reserve School of Medicine and leader ... cancer organization is funding the research with a three-year, ...
(Date:9/30/2014)... tourists visit the Mediterranean each year, but its ... on Earth. Almost 1,000 alien species, including fish, ... seas through human activities. In the open-access journal ... team of researchers analyzed data from a new ... show how the introduction of alien species has ...
Breaking Biology News(10 mins):CNBC Commercial Airings for Wocket Smart Wallet October 2nd and 3rd 2CNBC Commercial Airings for Wocket Smart Wallet October 2nd and 3rd 3Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3Biodiversity in the Mediterranean is threatened by alien species 2
... forms from solution is a problem that has occupied ... (TU/e), together with researchers from Germany and the USA, ... of crystal formation, which occurs widely in nature and ... years, but is saved now. The team made this ...
... known that horses show symptoms of stress when ridden but ... their riders. This is surprising, as equestrian sports rely ... How does the horse-rider team cope with the stress ... has now been studied by Mareike von Lewinski in the ...
... 2013 Raman spectroscopy has enabled incredible advances ... tool for tissue classification and disease recognition, although ... method in a clinical setting. Scientists have now ... the door to wider biomedical and clinical applications ...
Cached Biology News:Theory of crystal formation complete again 2Theory of crystal formation complete again 3Horses don't have stage fright -- but their riders do 2Breakthrough study opens door to broader biomedical applications for Raman spectroscopy 2
Profilin-1/2 (FL-140)...
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
HIV-1 TAT (vN-21)...
Biology Products: